An options strategy that bets on this medical device stock catching up to the rest of the market

Thirty-six buys, one hold and no sells: Medical device maker Boston Scientific is in pretty rarified air as far as Wall Street's sell-side analysts are concerned. Why is that? Much of the investment world's focus has rightly been directed at the AI build-out. It is, after all, a compelling growth story. However, there are other companies that have been growing rapidly, and for those seeking opportunities outside the AI sector, Boston Scientific (NYSE: BSX) may be worth considering. The company's strong presence in cardiology, endoscopy, and neuromodulation has contributed to impressive top and bottom-line growth. The second quarter this year continued the steady five-year trend of sales growth, with net sales reaching $5.06 billion, representing a 22.8% year-over-year increase. Adjusted ea